Welcome to our dedicated page for Turn Therapeutics SEC filings (Ticker: TTRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is intended to provide access to U.S. Securities and Exchange Commission (SEC) filings for Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company focused on dermatology, advanced wound care, infectious disease therapies, and intranasal vaccine initiatives. While no specific filings are listed in the provided data, Turn’s public communications reference its status as a Nasdaq-listed company and describe a direct listing structure used to enter the public markets.
For a company like Turn Therapeutics, investors typically look to annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed information on clinical programs such as GX-03 for moderate to severe atopic dermatitis, late-stage efforts in onychomycosis, and vaccine initiatives based on its PermaFusion delivery platform. These reports often include discussions of research and development spending, risk factors related to clinical trials and regulatory pathways, and descriptions of commercial agreements, such as the global supply, development, and license agreement with Medline.
Other important SEC documents for a Nasdaq-listed biotechnology company can include current reports on Form 8-K, which may disclose material events like new strategic partnerships, changes to the Board of Directors, or significant financing arrangements. Filings related to equity financing structures, such as the GEM Global Yield agreement and share purchase agreements referenced in company updates, are also commonly detailed in SEC submissions.
On Stock Titan, Turn Therapeutics filings are supplemented with AI-powered summaries designed to explain key sections of lengthy documents in clear language. These tools can help users quickly understand complex topics such as clinical development disclosures, collaboration terms, and capital strategy without reading every page. As new TTRX filings are made available through EDGAR, this page can serve as a starting point for reviewing the company’s regulatory and financial reporting history.
Turn Therapeutics Inc. entered into a growth capital loan agreement with Avenue Venture Opportunities Fund II for term loans of up to $25.0 million. An initial $7.0 million tranche is funded at closing, with up to $8.0 million in Tranche 2 and a discretionary Tranche 3 of up to $10.0 million tied to clinical and financing milestones and mutual agreement.
The loans bear interest at the greater of prime plus 5.50% or 12.25%, mature on October 1, 2029, and are secured by liens on all company assets, including intellectual property. Turn will make interest-only payments for at least 15 months, with potential extensions based on milestone achievement, followed by amortization to maturity.
As part of the deal, Turn paid a $150,000 commitment fee and agreed to a 3.75% final payment on aggregate funded amounts. The lender can convert up to $2.0 million of principal, rising to $3.0 million if Tranche 2 is funded, into common stock at 80% of the closing share price, and received an equity grant valued at $1.2 million. A participation right allows up to $1.0 million investment in future equity financings. A related press release states the financing is expected to extend Turn’s cash runway through its Phase 2 atopic dermatitis readout and potentially through the end of 2027.
Turn Therapeutics filed a current report to share a press release announcing that Robert Redfield, M.D., former Director of the U.S. Centers for Disease Control and Prevention, has been appointed Senior Advisor of Health Policy and Regulatory Affairs.
Dr. Redfield will advise on clinical development, public health considerations, and regulatory positioning of Turn’s lead investigational therapy, GX-03, which is in Phase 2 clinical trials. GX-03 is described as a first-in-class, non-systemic topical inhibitor in late-stage development for moderate-to-severe atopic dermatitis and other inflammatory dermatologic conditions.
Turn Therapeutics Inc. furnished a press release and updated investor presentation outlining upcoming appearances at the TD Cowen and Oppenheimer healthcare conferences and providing a detailed pipeline update. The company is developing GX-03, a first-in-class, non-systemic topical immunomodulator targeting IL-36, IL-31 and IL-4 for moderate-to-severe eczema, with a Phase 2 randomized controlled trial underway and topline results expected mid-2026.
The presentation highlights additional GX-03 opportunities in onychomycosis and psoriasis, plus a thermostable intranasal vaccine program enabled by the PermaFusion delivery platform. Turn reports raising about $21 million since 2015, cumulative cash burn of about $18 million, expected Phase 3 R&D spending of $55–60 million, and projected public-company G&A costs of about $250,000 per month. Existing device products are out-licensed to Medline and MiMedx with potential milestone payments exceeding $70 million.
Turn Therapeutics Inc. director Martin William Dewhurst received an award of 21,882 restricted stock units (RSUs) of common stock on January 7, 2026 at a price of $0 per unit. Each RSU represents the right to receive one share of common stock.
The 21,882 RSUs vest in full on January 7, 2027, provided Dewhurst continues to serve the company through that date. The award was made under Turn Therapeutics’ 2025 Omnibus Incentive Plan and is held directly by the reporting person.
Turn Therapeutics Inc. director Martin William Dewhurst filed an initial ownership report showing a stock option to buy 40,030 shares of common stock at an exercise price of $4.59 per share. The option became exercisable for 10,000 shares on July 26, 2024 and for 858 shares on the last day of each month thereafter, reflecting a 2-for-1 stock split that took effect on September 30, 2025. The option expires on July 26, 2034 and is held directly.
Turn Therapeutics Inc. filed a current report to furnish a company press release under Item 7.01 (Regulation FD Disclosure). The report notes that the press release, dated January 12, 2026 and attached as Exhibit 99.1, is being treated as information that is "furnished" rather than "filed" for purposes of the Securities Exchange Act of 1934. This means it is not subject to the liability provisions of Section 18 unless the company later specifically incorporates it by reference into a Securities Act or Exchange Act filing.
Turn Therapeutics Inc. expanded its board of directors from five to six members and appointed Martin Dewhurst as an independent Class III director, effective January 7, 2026. He will serve until the 2028 annual stockholders’ meeting, unless he leaves earlier, and will chair the board’s compensation committee.
Dewhurst brings more than 30 years of global life sciences leadership, including senior advisory roles at GHO Capital, PJT Partners, and LightRock, and prior experience as a senior partner at McKinsey & Co. In connection with his appointment, he received restricted stock units with a grant-date fair value of $100,000 under the 2025 Omnibus Incentive Plan, vesting on the first anniversary of the grant or upon a change of control, whichever occurs first. After the first anniversary of the company’s direct listing effective date, he will be eligible for an annual RSU grant with a grant-date fair value of $70,000. The company also furnished a press release and an updated investor presentation dated January 7, 2026.
Turn Therapeutics Inc. reported an insider stock purchase by officer Zuraiz Chaudhary. On 12/12/2025, Chaudhary bought 2,500 shares of common stock at $3.5 per share, bringing their directly held beneficial ownership to 12,500 shares.
Chaudhary serves as Interim Chief Financial Officer, Vice President of Finance and Chief Accounting Officer, and this report covers a single reporting person with direct ownership of the common stock.
Turn Therapeutics Inc. (TTRX) filed a Form 4 reporting a stock purchase by a director. On 11/24/2025, a reporting person serving as a director acquired 9,868 shares of Turn Therapeutics common stock in an open-market transaction coded "P" for purchase.
The weighted average purchase price was $3.44 per share, with individual trades executed between $3.25 and $3.50. Following this transaction, the reporting person beneficially owns 60,602 shares of Turn Therapeutics common stock, which includes restricted stock units granted under the company’s 2025 Omnibus Incentive Plan. Each RSU represents a right to receive one share of common stock, subject to vesting and continued service.
Turn Therapeutics Inc. (TTRX) reported an insider share purchase by a director. On 11/21/2025, the reporting person bought 20,532 shares of common stock in an open-market transaction at a weighted average price of $2.87 per share, with individual trades ranging from $2.66 to $3.25. After this transaction, the director beneficially owns 50,734 shares of common stock.
Certain shares in this total are restricted stock units (RSUs) granted under Turn Therapeutics’ 2025 Omnibus Incentive Plan, each RSU representing a right to receive one common share if vesting conditions and continued service requirements are satisfied.